Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database

INTRODUCTION: Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is effective in patients with type 2 diabetes (T2D), but treatment discontinuation without new T2D therapy initiation may compromise outcomes. METHODS: This retrospective cohort study (July 1, 2012, to December 31, 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Uzoigwe, Chioma, Noone, Josh, Liang, Yuanjie, Ali, Sarah Naz, Gamble, Cory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663787/
https://www.ncbi.nlm.nih.gov/pubmed/36239850
http://dx.doi.org/10.1007/s13300-022-01322-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663787/
https://www.ncbi.nlm.nih.gov/pubmed/36239850
http://dx.doi.org/10.1007/s13300-022-01322-z

Ejemplares similares